Javascript must be enabled to continue!
Hashimoto thyroiditis interfered with BRAF V600E mutation in papillary thyroid cancer
View through CrossRef
AbstractPurposeTo investigate the possibly predictive role of BRAF V600E mutation and thyroid-relevant indexes on papillary thyroid cancer (PTC).Methods1139 patients of PTC were included in this retrospective study. The pathological results, demographic characteristics data, BRAF V600E mutation, and serum examination of thyroid were analyzed by Chi‐square tests and logistic regressions.ResultsThe patients at a high level of thyroglobulin antibody (TgAb), thyroid peroxidase antibody (TPOAb), or Hashimoto's thyroiditis (HT) had lower rates of BRAF V600E mutation. Elevated thyroglobulin was associated with a higher rate of macro-carcinoma regardless of the mutation statuses (P<0.001), extrathyroidal invasion (P = 0.026), and lymph node metastases (P = 0.020) in a non-mutation group. The rates of macro-carcinoma and extrathyroidal invasion increased with body mass index (P<0.05). Abnormally high TgAb decreased the occurrence of multiple lesions (P = 0.014). Obesity, smoking, and high thyroglobulin increased the rate of macro-carcinoma (P<0.05), and obesity slightly fostered extrathyroidal invasion (P=0.005). The young and male patients were at elevated risk of lymph node metastases (P<0.001). There was no statistical significance in major features of PTC between the different statuseses of BRAF V600E mutation (P>0.05).ConclusionBRAF V600E mutation and HT interfered with each other in PTC. HT manifested a protective role against the progression of this cancer in the early period, but the mutation didn't impact the features. The tumor load was reflected by thyroglobulin and body mass index.
Title: Hashimoto thyroiditis interfered with BRAF V600E mutation in papillary thyroid cancer
Description:
AbstractPurposeTo investigate the possibly predictive role of BRAF V600E mutation and thyroid-relevant indexes on papillary thyroid cancer (PTC).
Methods1139 patients of PTC were included in this retrospective study.
The pathological results, demographic characteristics data, BRAF V600E mutation, and serum examination of thyroid were analyzed by Chi‐square tests and logistic regressions.
ResultsThe patients at a high level of thyroglobulin antibody (TgAb), thyroid peroxidase antibody (TPOAb), or Hashimoto's thyroiditis (HT) had lower rates of BRAF V600E mutation.
Elevated thyroglobulin was associated with a higher rate of macro-carcinoma regardless of the mutation statuses (P<0.
001), extrathyroidal invasion (P = 0.
026), and lymph node metastases (P = 0.
020) in a non-mutation group.
The rates of macro-carcinoma and extrathyroidal invasion increased with body mass index (P<0.
05).
Abnormally high TgAb decreased the occurrence of multiple lesions (P = 0.
014).
Obesity, smoking, and high thyroglobulin increased the rate of macro-carcinoma (P<0.
05), and obesity slightly fostered extrathyroidal invasion (P=0.
005).
The young and male patients were at elevated risk of lymph node metastases (P<0.
001).
There was no statistical significance in major features of PTC between the different statuseses of BRAF V600E mutation (P>0.
05).
ConclusionBRAF V600E mutation and HT interfered with each other in PTC.
HT manifested a protective role against the progression of this cancer in the early period, but the mutation didn't impact the features.
The tumor load was reflected by thyroglobulin and body mass index.
Related Results
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Abstract
Introduction
Non-Hodgkin lymphoma (NHL) of the thyroid, a rare malignancy linked to autoimmune disorders, is poorly understood in terms of its pathogenesis and treatment o...
Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
Background: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to ...
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Abstract
Introduction
Due to indeterminate cytology, Bethesda III is the most controversial category within the Bethesda System for Reporting Thyroid Cytopathology. This study exam...
Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated non-small cell lung cancer (NSCLC).
Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated non-small cell lung cancer (NSCLC).
e21745 Background: BRAF mutations are infrequently seen in non-small cell lung cancer (NSCLC) in Chinese population. We aimed to investigate the clinicopathologic characteristics ...
Detection of Pan Braf in Thyroid Tumors in Iraqi Patients
Detection of Pan Braf in Thyroid Tumors in Iraqi Patients
The B-type Raf kinase (BRAF) is a member of RAS\RAF\MEK\ERK pathway and this pathway can lead to increased cellular growth, invasion and metastasis. The mutated BRAF protein activa...
Relationship between serum NDRG3 and papillary thyroid carcinoma
Relationship between serum NDRG3 and papillary thyroid carcinoma
BackgroundIn recent years, papillary thyroid carcinoma is considered to be one of the fastest increaseing cancer. NDRG family member 3 (NDRG3) has been proposed as a molecular mark...
Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test
Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test
The BRAF V600E mutation is an important oncological target in certain central nervous system (CNS) tumors, for which a possible application of BRAF-targeted therapy grows continuou...
Real world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: The COALA project.
Real world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: The COALA project.
70
Background:
BRAFV600E-mutant metastatic colorectal cancer (mCRC) represents a unique molecular subset with poor prognosis and less ...

